Can Fite Biopharma Ltd ADR (CANF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Can Fite Biopharma Ltd ADR (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Can Fite Biopharma Ltd ADR to measure how many days the company can operate on defensive assets alone.
Can Fite Biopharma Ltd ADR - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Can Fite Biopharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Can Fite Biopharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Can Fite Biopharma Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Novavis Group SA
WAR:NVG
|
-2.375x |
|
Moving iMage Technologies Inc
NYSE MKT:MITQ
|
0.523x |
|
Critical Minerals Group Ltd
AU:CMG
|
0.171x |
|
Agro Yasa Lestari PT Tbk
JK:AYLS
|
0.020x |
|
Amaze Holdings Inc
NYSE MKT:AMZE
|
1.001x |
|
Osia Hyper Retail Limited
NSE:OSIAHYPER
|
-0.012x |
|
Avant Brands Inc
TO:AVNT
|
0.015x |
|
Dreamland Limited Class A Ordinary Shares
NASDAQ:TDIC
|
-0.910x |
Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd ADR (2011–2025)
The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd ADR from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Can Fite Biopharma Ltd ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.59 Million | $-9.02 Million | -1.613x | -14.82% |
| 2024-12-31 | $5.44 Million | $-7.64 Million | -1.405x | -3.92% |
| 2023-12-31 | $6.24 Million | $-8.44 Million | -1.352x | +44.03% |
| 2022-12-31 | $4.47 Million | $-10.80 Million | -2.415x | -252.36% |
| 2021-12-31 | $14.38 Million | $-9.86 Million | -0.685x | +65.49% |
| 2020-12-31 | $6.07 Million | $-12.06 Million | -1.986x | +55.24% |
| 2019-12-31 | $2.44 Million | $-10.83 Million | -4.437x | -221.93% |
| 2018-12-31 | $3.02 Million | $-4.16 Million | -1.378x | +55.81% |
| 2017-12-31 | $3.05 Million | $-9.52 Million | -3.118x | -35.33% |
| 2016-12-31 | $3.87 Million | $-8.93 Million | -2.304x | -417.41% |
| 2015-12-31 | $10.44 Million | $-4.65 Million | -0.445x | +58.32% |
| 2014-12-31 | $6.86 Million | $-7.33 Million | -1.069x | +44.80% |
| 2013-12-31 | $4.46 Million | $-8.63 Million | -1.936x | -131.52% |
| 2012-12-31 | $-707.99K | $-4.35 Million | 6.141x | +467.80% |
| 2011-12-31 | $3.29 Million | $-5.50 Million | -1.670x | -- |
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more